<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17403" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alport Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Watson</surname>
            <given-names>Simon</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padala</surname>
            <given-names>Sandeep A.</given-names>
          </name>
          <aff>Augusta UMC/ Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bush</surname>
            <given-names>Jeffrey S.</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Simon Watson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Padala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Bush declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17403.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Alport syndrome is a genetic condition characterized by kidney disease, loss of hearing, and eye abnormalities. It occurs due to an abnormality of a gene that codes for type 4 collagen and usually presents in patients with hematuria, edema, and hypertension. In 80% of cases, Alport syndrome is inherited in an X-linked pattern and caused by COL4A5 gene mutations, although other inheritance patterns exist. It can be inherited as an autosomal recessive or dominant pattern by mutations in COL4A3 or COL4A4 gene. This activity illustrates the evaluation and management of Alport syndrome and reviews the role of the interprofessional team in improving care for patients suffering from this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of Alport syndrome.</p></list-item><list-item><p>Summarize the pathophysiology of Alport syndrome.</p></list-item><list-item><p>Describe the use of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin 2 receptor blockers (ARBs) in managing Alport syndrome.</p></list-item><list-item><p>Outline the importance of collaboration and communication among the interprofessional team to enhance care coordination for patients affected by Alport syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17403&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17403">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17403.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The term Alport syndrome is used to describe a group of heterogeneous inherited disorders involving the basement membrane of the kidney and commonly affecting the cochlea and eye.<xref ref-type="bibr" rid="article-17403.r1">[1]</xref><xref ref-type="bibr" rid="article-17403.r2">[2]</xref> Alport syndrome, also known as hereditary nephritis, is a genetic disorder&#x000a0;arising from the mutations in the genes encoding alpha-3, alpha-4, and alpha-5 of&#x000a0;type 4 collagen (COL4A3, COL4A4, COL4A5) or collagen 4 &#x003b1;345 network.<xref ref-type="bibr" rid="article-17403.r3">[3]</xref></p>
        <p>The type 4 collagen alpha chains are primarily located in the kidneys, eyes, and cochlea. Alport syndrome is X-linked (XLAS) and can be transmitted in an autosomal recessive (ARAS) or autosomal dominant fashion (ADAS).&#x000a0;In 1927, the syndrome of hereditary nephritis and deafness was described by a British physician, A. Cecil Alport. It was&#x000a0;observed that hematuria was the most common symptom, and males were affected more than females. In 1961, it was named Alport syndrome after having been&#x000a0;observed in multiple family members.<xref ref-type="bibr" rid="article-17403.r4">[4]</xref><xref ref-type="bibr" rid="article-17403.r5">[5]</xref><xref ref-type="bibr" rid="article-17403.r6">[6]</xref>&#x000a0;It is&#x000a0;characterized&#x000a0;by renal failure, bilateral sensorineural hearing loss, and eye abnormalities. Eventually, the patients present with proteinuria, hypertension, progressive loss of kidney function (gradual decline in GFR), and end-stage renal disease (ESRD).<xref ref-type="bibr" rid="article-17403.r7">[7]</xref><bold/></p>
      </sec>
      <sec id="article-17403.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>In 80% of cases, Alport syndrome is inherited in an X-linked pattern and caused by&#x000a0;<italic toggle="yes">COL4A5</italic> gene&#x000a0;mutations, although other inheritance patterns exist. It can be inherited as an autosomal recessive or dominant&#x000a0;pattern by mutations in&#x000a0;<italic toggle="yes">COL4A3</italic> or <italic toggle="yes">COL4A4</italic> gene. Approximately 80% of men with XLAS&#x000a0;develop some hearing loss until they reach their teenage years.<xref ref-type="bibr" rid="article-17403.r8">[8]</xref></p>
        <p>Alport syndrome is caused by mutations in the genes responsible for alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The following three genetic forms of Alport syndrome are mentioned with their proximate causes:</p>
        <list list-type="bullet">
          <list-item>
            <p>XLAS - caused by mutations in the&#x000a0;<italic toggle="yes">COL4A5</italic>&#x000a0;gene; 85% of cases of Alport syndrome<xref ref-type="bibr" rid="article-17403.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>ARAS - due to mutations in&#x000a0;<italic toggle="yes">COL4A3</italic>&#x000a0;or&#x000a0;<italic toggle="yes">COL4A4</italic>&#x000a0;gene; leading to approximately 10-15% of cases</p>
          </list-item>
          <list-item>
            <p>ADAS - caused by mutations in the&#x000a0;<italic toggle="yes">COL4A3</italic>&#x000a0;or&#x000a0;<italic toggle="yes">COL4A4</italic>&#x000a0;gene, although rare&#x000a0;</p>
          </list-item>
        </list>
        <p>Over 300 mutations have been observed in the&#x000a0;<italic toggle="yes">COL4A5</italic>&#x000a0;genes in families with XLAS. Majorly,&#x000a0;<italic toggle="yes">COL4A5</italic>&#x000a0;mutations are minor, including splice-site mutations, missense mutations, and deletions of fewer than ten base pairs.</p>
        <p>Around 20% of the mutations are large and medium-sized deletions in the&#x000a0;<italic toggle="yes">COL4A5</italic>&#x000a0;gene. A certain kind of deletion involving the&#x000a0;<italic toggle="yes">COL4A5</italic>&#x000a0;and&#x000a0;<italic toggle="yes">COL4A6</italic>&#x000a0;genes leads to a combination of XLAS and leiomyomatosis of the esophagus, female genital tract, and tracheobronchial tree.<xref ref-type="bibr" rid="article-17403.r10">[10]</xref></p>
        <p>In patients with Alport syndrome, to date, only six mutations in the&#x000a0;<italic toggle="yes">COL4A3</italic>&#x000a0;gene and twelve mutations in the&#x000a0;<italic toggle="yes">COL4A4</italic>&#x000a0;gene are seen in patients with ARAS. The mutations include frameshift deletions, amino acid substitutions, missense mutations, splicing mutations, and in-frame deletions.</p>
      </sec>
      <sec id="article-17403.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Alport syndrome affects about 1 in 50,000 newborns, and males are more likely to be symptomatic than females. It is estimated that approximately 30,000 to 60,000 people in the United States (US) have this disorder. In the US,&#x000a0;the overall incidence of end-stage renal disease (ESRD) in children is about 3% and 0.2% in the adult population.<xref ref-type="bibr" rid="article-17403.r11">[11]</xref><xref ref-type="bibr" rid="article-17403.r12">[12]</xref></p>
        <p>Alport syndrome accounts for approximately 2.2% of children and 0.2% of adults with ESRD in the United States. In Europe, Alport syndrome accounts for 0.6% of patients with ESRD.</p>
        <p>The common X-linked type of Alport syndrome resulting in ESRD predominantly affects males. However, the X-linked form of Alport syndrome affects almost as many females. Affected women are generally undiagnosed, but 15%&#x02013;30% end up having renal failure by 60 years and hearing loss by middle age.<xref ref-type="bibr" rid="article-17403.r13">[13]</xref></p>
        <p>Alport syndrome is a significant cause of chronic kidney disease (CKD), leading to ESRD in adolescents and young adults, accounting for 1.5%&#x000a0;to 3.0% of children on renal replacement therapies in Europe and the US.<xref ref-type="bibr" rid="article-17403.r14">[14]</xref></p>
      </sec>
      <sec id="article-17403.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of Alport syndrome is impaired production and deposition of collagen 4 &#x003b1;345 network in the basement membranes of the glomerulus, cochlea (inner ear), and eye. ARAS transmission is due to mutations in both the alleles of COL4A3 and COL4A4, whereas ADAS is caused by heterozygous mutations. With the use of next-generation sequencing (NGS), it has been shown that ADAS accounts for a greater number of cases. Compared to XLAS, patients with ADAS have a slower rate of progression to ESRD and are less likely to have extra-renal manifestations.<xref ref-type="bibr" rid="article-17403.r15">[15]</xref><xref ref-type="bibr" rid="article-17403.r16">[16]</xref>&#x000a0;The glomerular basement membrane (GBM) in Alport syndrome is more prone to proteolytic injury leading to activation of adhesion kinase in podocytes, endothelin receptors, glomerular inflammation, tubulointerstitial fibrosis, and ESRD.<xref ref-type="bibr" rid="article-17403.r17">[17]</xref><xref ref-type="bibr" rid="article-17403.r18">[18]</xref><xref ref-type="bibr" rid="article-17403.r19">[19]</xref><xref ref-type="bibr" rid="article-17403.r20">[20]</xref></p>
        <p>The primary pathology in patients with Alport syndrome&#x02014;causing abnormality in the basement membrane&#x02014;is present in the noncollagenous (NC1) C-terminal of the alpha-5 chain in XLAS and that of alpha-3 or alpha-4 chains in ARAS and ADAS.</p>
        <p>In the early development of the kidney, alpha-1 and alpha-2 chains are predominant in the glomerular basement membrane (GBM). With maturation, alpha-3, alpha-4, and alpha-5 chains become dominant&#x000a0;through isotype switching. Evidence suggests that alpha-3, alpha-4, and alpha-5 chains combine to produce a unique collagen network. Abnormalities in any of these chains, as seen in patients with Alport syndrome, impair the formation of the collagen network leading to aberrant incorporation of the other collagen chains.&#x000a0;</p>
        <p>Evidence shows that isoform switching of type IV collagen is developmentally arrested in XLAS.<xref ref-type="bibr" rid="article-17403.r21">[21]</xref>&#x000a0;This causes the&#x000a0;perpetuation of the fetal distribution of alpha-1 and alpha-2 isoforms and a complete lack of alpha-3, alpha-4, and alpha-5 isoforms. The anomalous retention of alpha-1 and alpha-2 isoforms makes GBM prone to proteolytic enzymes, causing basement membrane splitting and damage.</p>
        <p>Patients who develop anti-GBM nephritis have circulating anti-GBM antibodies. In patients with ARAS, antibodies bind to the alpha-3 and alpha-4 collagen chains, whereas in patients with XLAS, antibodies predominantly bind to the alpha-5 chain.<xref ref-type="bibr" rid="article-17403.r22">[22]</xref><xref ref-type="bibr" rid="article-17403.r23">[23]</xref><xref ref-type="bibr" rid="article-17403.r24">[24]</xref>&#x000a0;Native kidneys do not express the antigens recognized by the anti-GBM antibodies&#x000a0;but are expressed in the transplanted kidneys, which are recognized by these antibodies.</p>
        <p>Posttransplant anti-GBM nephritis generally&#x000a0;appears within the first year of transplant. Patients have rapidly progressive glomerulonephritis with kidney biopsy revealing linear immune deposits along the GBM and crescentic glomerulonephritis. Contrary to de novo anti-GBM nephritis, lung hemorrhage is never seen in posttransplant anti-GBM nephritis in cases of Alport syndrome. Plasmapheresis and cyclophosphamide are generally unsuccessful, and most patients lose the allograft.<xref ref-type="bibr" rid="article-17403.r25">[25]</xref> However, there have been cases of successful treatment with intravenous immunoglobulins and plasmapheresis.</p>
      </sec>
      <sec id="article-17403.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Initially, kidney biopsy specimens examined through light microscopy may be normal. As the disease progresses, non-specific findings may appear. These include focal and segmental glomerulosclerosis, tubular atrophy, interstitial fibrosis, and the presence of lymphocytes and plasma cells. Immunofluorescence studies yield negative results. Electron microscopy of the kidney reveals longitudinal splitting and multi-lamellation of the GBM lamina densa.<xref ref-type="bibr" rid="article-17403.r26">[26]</xref>&#x000a0;Monoclonal antibodies against alpha-3, alpha-4, and alpha-5 chains of type IV collagen may be used to assess the glomerular basement membrane for the presence or absence of these collagen chains. Their absence is strongly suggestive of Alport syndrome and is not seen in any other condition.</p>
        <p>As the alpha-5 chain of type 4 collagen is also expressed in the epidermis, a skin biopsy can be used to establish a diagnosis. Immunofluorescence studies on skin biopsy specimens are often diagnostic. Patients with XLAS may also display abnormalities of alpha-2 collagen expression in the skin.<xref ref-type="bibr" rid="article-17403.r27">[27]</xref><xref ref-type="bibr" rid="article-17403.r28">[28]</xref></p>
      </sec>
      <sec id="article-17403.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical examination must be obtained along with a family history. Laboratory evaluation&#x000a0;should include&#x000a0;urinalysis (UA), urine microscopy, and&#x000a0;renal function panel. Individuals with Alport syndrome may develop symptoms of hematuria, proteinuria, edema, hypertension, progressive decline in renal functions, and eventual ESRD. Over time, the symptoms worsen, and the patients experience worsening proteinuria, hypertension, a decline in GFR, and the development of ESRD. The time for the development of ESRD is around 16 to 35 years of age. They can also present with gross hematuria following an upper respiratory tract infection.<xref ref-type="bibr" rid="article-17403.r29">[29]</xref></p>
        <p>During late childhood, people with Alport syndrome frequently develop bilateral sensorineural hearing loss caused by abnormalities of type 4 collagen in the inner ear.<xref ref-type="bibr" rid="article-17403.r30">[30]</xref> Hearing loss becomes apparent in late childhood or early adolescence, usually before the onset of kidney failure, and starts with high-frequency loss.</p>
        <p>Multiple ocular findings can be seen&#x000a0;in patients with Alport syndrome. Affected individuals may have a cone-shaped lens (anterior lenticonus),&#x000a0;leading to abnormal refraction and decreased visual acuity.&#x000a0;Other abnormalities include&#x000a0;subcapsular cataracts, abnormal pigmentary changes in the retina with yellow or white flecks (dot-and-fleck retinopathy),&#x000a0;posterior polymorphous dystrophy, and corneal erosions.<xref ref-type="bibr" rid="article-17403.r31">[31]</xref><xref ref-type="bibr" rid="article-17403.r32">[32]</xref><xref ref-type="bibr" rid="article-17403.r33">[33]</xref><xref ref-type="bibr" rid="article-17403.r34">[34]</xref></p>
        <p>The following are the features in the history and examination, system-wise:</p>
        <p>
<bold>Renal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gross or microscopic hematuria is the commonest and earliest sign of Alport syndrome.<xref ref-type="bibr" rid="article-17403.r35">[35]</xref> It is more commonly seen in males. Like immunoglobulin, A nephropathy, around 60-70% of patients have episodes of gross hematuria, commonly precipitated by upper respiratory infection, in the first two decades of life. Hematuria is typically discovered in the first years of life in male patients. If there is no hematuria in a male patient in the first decade of life, he is less likely to have Alport syndrome.</p>
          </list-item>
          <list-item>
            <p>Proteinuria is generally absent in childhood but ultimately develops in males with XLAS and male and female patients with ARAS.<xref ref-type="bibr" rid="article-17403.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Incidence and severity increase with age and the extent of kidney failure.</p>
          </list-item>
          <list-item>
            <p>Hypertension develops by the second decade of life.</p>
          </list-item>
          <list-item>
            <p>Edema and nephrotic syndrome are observed in 30&#x000a0;to 40% of young patients with Alport syndrome; however, they are uncommon in early childhood.</p>
          </list-item>
          <list-item>
            <p>With the onset of kidney insufficiency, chronic anemia and osteodystrophy may manifest.</p>
          </list-item>
        </list>
        <p>
<bold>Hearing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sensorineural&#x000a0;hearing loss is a characteristic feature observed commonly, but not universally, in Alport syndrome. Hearing loss is never congenital. Bilateral, high-frequency sensorineural deafness usually begins in late childhood or early adolescence, before the onset of kidney failure. Audiometry is an important tool to diagnose hearing loss at the beginning of the disease.</p>
          </list-item>
          <list-item>
            <p>As hearing loss progresses, patients require hearing aids.</p>
          </list-item>
          <list-item>
            <p>Hearing loss is always associated with renal involvement.</p>
          </list-item>
          <list-item>
            <p>Approximately 50% of male patients with XLAS have sensorineural&#x000a0;hearing impairment by the age of 25 years, and around 90% are deaf by 40 years.</p>
          </list-item>
        </list>
        <p>
<bold>Ocular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anterior lenticonus, occurring in around 25% of patients with XLAS, is a characteristic feature of Alport syndrome. In this condition, the lens conically protrudes into the anterior chamber due to a thin basement membrane of the lens capsule.</p>
          </list-item>
          <list-item>
            <p>Anterior lenticonus is generally not present at birth and is manifested by a slow worsening of vision, needing patients to change the prescription of their glasses frequently.</p>
          </list-item>
          <list-item>
            <p>Anterior lenticonus is diagnosed by slit lamp examination.</p>
          </list-item>
          <list-item>
            <p>Ultrastructure&#x000a0;assessment of the anterior lens capsule with the help of electron microscopy confirms Alport syndrome.<xref ref-type="bibr" rid="article-17403.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Dot-and-fleck retinopathy&#x000a0;is the commonest ocular manifestation of Alport syndrome, occurring in around 85% of males with XLAS. Rarely seen in childhood, it typically appears at the onset of kidney failure. It is usually asymptomatic.&#x000a0;Numerous white and yellow dots and flecks occur around the macula in this condition. There is foveal sparing, but peripheries can get involved. Typically, dot-and-fleck retinopathy will not fluoresce with angiography.</p>
          </list-item>
          <list-item>
            <p>Posterior polymorphous corneal dystrophy&#x000a0;is rare in Alport&#x000a0;syndrome. Mostly, patients are asymptomatic, but some may develop gradually progressive visual impairment.&#x000a0;A rare&#x000a0;feature of Alport syndrome, it manifests as clear vesicles on the endothelial surface of the cornea. It is generally bilateral but can be unilateral.</p>
          </list-item>
          <list-item>
            <p>The mutation in the&#x000a0;COL4A5&#x000a0;gene rarely causes severe temporal macular thinning, a feature associated with XLAS.<xref ref-type="bibr" rid="article-17403.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Giant macular holes have been&#x000a0;reported in Alport syndrome case reports. The very large dimensions of macular holes were suggestive of a bad prognosis regarding the closure of the hole.<xref ref-type="bibr" rid="article-17403.r39">[39]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Leiomyomatosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse leiomyomatosis of the tracheobronchial tree and&#x000a0;esophagus has been observed in some families with Alport syndrome.<xref ref-type="bibr" rid="article-17403.r40">[40]</xref> It generally becomes symptomatic in late childhood, and symptoms include dysphagia, postprandial vomiting, recurrent bronchitis, substernal or epigastric pain, dyspnea, stridor, and cough. Leiomyomatosis is confirmed on a computed tomography scan or magnetic resonance imaging.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17403.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients typically present with persistent microscopic hematuria before the age of ten years. This is due to the defective glomerular basement membrane (GBM) permitting the passage of red blood cells.<xref ref-type="bibr" rid="article-17403.r41">[41]</xref>&#x000a0;The clinical suspicion for Alport syndrome should be high in patients with hematuria, proteinuria, abnormal renal indices, and ear and eye manifestations.&#x000a0;UA&#x000a0;would reveal blood and protein, and urine microscopy should be performed to evaluate for acanthocytes.</p>
        <p>Renal biopsy is indicated in the setting of abnormal UA, presence of acanthocytes, red blood cell casts, or abnormal renal indices. Any patient with suspected Alport syndrome should be referred to otorhinolaryngology for the evaluation of high-frequency hearing loss and ophthalmology for the eye examination. Due to the defective collagen, the lens lacks the integrity to maintain the normal shape leading to the anterior lenticonus into the anterior chamber.<xref ref-type="bibr" rid="article-17403.r42">[42]</xref><xref ref-type="bibr" rid="article-17403.r43">[43]</xref></p>
        <p>Genetic testing can help establish the diagnosis and determine the inheritance pattern of an individual and their family members. Molecular genetic testing is non-invasive, accurate, and gives the prognosis as the underlying mutation can be revealed. Next-generation sequencing (NGS) analyses of COL4A3, COL4A4, and COL4A5 are recommended in patients with no family history of Alport syndrome.<xref ref-type="bibr" rid="article-17403.r15">[15]</xref><xref ref-type="bibr" rid="article-17403.r44">[44]</xref>&#x000a0;For patients with positive family history, testing the target gene is recommended. A renal biopsy is preferred if the genetic defect does not match the family genetic mutation. In males with XLAS, the GBM splitting increases from approximately 30% to more than 90% by the age of 30 years.<xref ref-type="bibr" rid="article-17403.r45">[45]</xref></p>
        <p>Patients without the characteristic GBM splitting can be identified by&#x000a0;immunostaining&#x000a0;the type 4 collagen of the alpha-3, alpha-4, and alpha-5 chains of the GBM. A less invasive procedure, a skin biopsy can be performed on a child with suspected&#x000a0;XLAS&#x000a0;using a monoclonal antibody against the alpha-5 of the type 4 collagen chain.</p>
      </sec>
      <sec id="article-17403.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Unfortunately, there is no specific treatment for Alport syndrome. Treatment is focused on limiting the progression of proteinuria and kidney disease. Options include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) for managing proteinuria, hypertension, and CKD. Depending upon the degree of proteinuria, diuretics can be used. Although the treatment may delay the onset of renal impairment, most people affected by Alport will ultimately require dialysis or a kidney transplant.<xref ref-type="bibr" rid="article-17403.r46">[46]</xref><xref ref-type="bibr" rid="article-17403.r47">[47]</xref><xref ref-type="bibr" rid="article-17403.r1">[1]</xref></p>
        <p>ARB delays the progression of CKD or ESRD by reducing intra-glomerular pressure and proteinuria. Despite normal renal functions, initiating therapy with ARBs has been shown to have a significant impact on the development of ESRD.<xref ref-type="bibr" rid="article-17403.r48">[48]</xref></p>
        <p>A small study found that combination therapy with an ARB, an ACE inhibitor, a statin, and a non-dihydropyridine calcium channel blocker safely ameliorated hypertension, albuminuria, lipid abnormalities, and glomerular selectivity in patients with Alport syndrome and halted progression in those without renal insufficiency.<xref ref-type="bibr" rid="article-17403.r49">[49]</xref></p>
        <p>A multicenter, placebo-controlled, randomized, double-blind trial of ramipril in children having Alport syndrome observed a decrease in the risk of disease progression by nearly half.<xref ref-type="bibr" rid="article-17403.r50">[50]</xref></p>
        <p>The use of cyclosporine has not shown any benefit and is not recommended. For patients with ocular involvement, specifically anterior lenticonus, clear lens phacoemulsification with intraocular lens implantation can be considered. For patients with concomitant hearing loss, hearing aids are usually very effective. Hearing loss is not impacted by kidney transplantation. As with any hereditary disease, psychosocial support for all affected family members is essential.<xref ref-type="bibr" rid="article-17403.r51">[51]</xref></p>
        <p>Patients with Alport syndrome have no contraindication for renal transplantation. There is no recurrence of the primary disease, as the transplanted kidney would have normal GBM.&#x000a0;Antibodies against&#x000a0;COL4A5 are found in males with&#x000a0;XLAS,&#x000a0;but very few patients also have antibodies against COL4A3.<xref ref-type="bibr" rid="article-17403.r52">[52]</xref><xref ref-type="bibr" rid="article-17403.r53">[53]</xref><xref ref-type="bibr" rid="article-17403.r54">[54]</xref><xref ref-type="bibr" rid="article-17403.r55">[55]</xref></p>
        <p>Post renal transplantation, there is a 3% risk of de novo anti-GBM antibody disease or Alport posttransplant nephritis in XLAS with COL4A3. Generally, it relapses in the first year of transplantation.<xref ref-type="bibr" rid="article-17403.r32">[32]</xref><xref ref-type="bibr" rid="article-17403.r56">[56]</xref><xref ref-type="bibr" rid="article-17403.r57">[57]</xref></p>
        <p>The affected patients typically possess circulating anti-GBM antibodies leading to crescentic glomerulonephritis and graft loss.<xref ref-type="bibr" rid="article-17403.r58">[58]</xref><xref ref-type="bibr" rid="article-17403.r59">[59]</xref>&#x000a0;Patients with ADAS do not appear to be at increased risk for de novo anti-GBM disease&#x000a0;following kidney transplantation. The treatment of post-transplant anti-GBM disease involves plasmapheresis along with cyclophosphamide and methylprednisolone with minimal benefit. Retransplantation in these patients has&#x000a0;a high risk of recurrence.</p>
      </sec>
      <sec id="article-17403.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses of Alport syndrome include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immunoglobulin A nephropathy</p>
          </list-item>
          <list-item>
            <p>Thin GBM disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute post-streptococcal glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Medullary cystic disease</p>
          </list-item>
          <list-item>
            <p>Multicystic renal dysplasia</p>
          </list-item>
          <list-item>
            <p>Polycystic kidney disease</p>
          </list-item>
        </list>
        <p>The most important diagnostic consideration in patients with Alport syndrome is thin basement membrane (TBM) disease, a collagen 4-related nephropathy closely related to Alport syndrome. The same genes appear to be involved in many individuals with the disorder. Unlike those with Alport syndrome, few extra-renal findings are present, symptoms are less severe, with progression to renal impairment is rarely found. Differentiating these disease processes is challenging, particularly in younger or female patients who are less likely to have other associated symptoms.<xref ref-type="bibr" rid="article-17403.r60">[60]</xref></p>
      </sec>
      <sec id="article-17403.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In the X-linked disease form, the most common type of Alport syndrome, about 50% of males require dialysis or kidney transplantation by 30 years, and approximately 90% develop ESRD before 40.<xref ref-type="bibr" rid="article-17403.r61">[61]</xref> Female patients with X-linked Alport syndrome have a better prognosis, with about 12% developing end-stage renal disease (ESRD) by age 40. However, studies&#x000a0;indicate significant renal morbidity in females with proteinuria and hearing impairment.<xref ref-type="bibr" rid="article-17403.r62">[62]</xref><xref ref-type="bibr" rid="article-17403.r63">[63]</xref></p>
        <p>By age 60, this rate increases to about 30%, and by 60 years of age, the rate of ESRD approaches 40%. In the female population, proteinuria and hearing loss are risk factors for the progression to ESRD. In comparison, the autosomal recessive form of Alport syndrome can cause kidney failure by age 20. In contrast, the autosomal dominant form of the disease typically has a delay in ESRD until middle age.<xref ref-type="bibr" rid="article-17403.r64">[64]</xref><bold/></p>
      </sec>
      <sec id="article-17403.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Alport syndrome affects multiple organ systems. It can lead to the following complications:</p>
        <list list-type="bullet">
          <list-item>
            <p>End-stage renal disease (ESRD)</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Visual defects</p>
          </list-item>
          <list-item>
            <p>Leiomyomatosis (smooth muscle overgrowth in the respiratory and gastrointestinal tract)</p>
          </list-item>
          <list-item>
            <p>Aneurysms of the thoracic and abdominal aorta</p>
          </list-item>
          <list-item>
            <p>Mental retardation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17403.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Alport syndrome is managed through a multidisciplinary approach as multiple organ systems are involved. An internist, intensivist, nephrologist, otorhinolaryngologist, ophthalmologist, and geneticist are involved in treating and managing Alport syndrome.&#x000a0;</p>
        <p>Consultations with the following may also be necessary:</p>
        <list list-type="bullet">
          <list-item>
            <p>Transplant surgeon</p>
          </list-item>
          <list-item>
            <p>Surgeon</p>
          </list-item>
          <list-item>
            <p>Dialysis specialist</p>
          </list-item>
          <list-item>
            <p>Audiologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17403.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be given information leaflets regarding symptoms of renal failure and its systemic effects. Parents of affected children should be knowledgeable about the signs and symptoms of the disease that warrant hospital admission. Family members of patients with Alport syndrome should consult their primary care providers to go through screening as per the local guidelines. Patients with Alport syndrome should undergo genetic counseling before getting married and having children. There are various support groups available that can help patients and their families have better handling of their circumstances.</p>
      </sec>
      <sec id="article-17403.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Alport syndrome is a genetic disorder that affects multiple organs. The condition is best managed by an interprofessional team that includes a geneticist, nephrologist, ophthalmologist, otolaryngologist, and internist/pediatrician. Nurses and pharmacists are also part of this interprofessional team, counseling patients and working with their medications. In most cases, the disorder presents&#x000a0;during the first decade of life. Once the diagnosis is made, the workup of siblings and other family members is&#x000a0;recommended. Within the first three decades of life, most Alport syndrome patients develop ESRD and need dialysis. Here again, nurses and pharmacists will play a prominent role, the former in administering dialysis and the latter in fine-tuning drug dosing regimens around dialysis. All care team members must exercise open communication with the rest of the team and maintain accurate, updated records to ensure open information sharing among all professionals on the case.</p>
        <p>Collaboration and communication among the interprofessional team to enhance care coordination for patients&#x000a0;suffering from Alport syndrome is crucial to optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17403.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17403&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17403">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/alport-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17403">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17403/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17403">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17403.s17">
        <fig id="article-17403.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Kidney biopsy showing glomeruli in Alport syndrome. Contributed by Rian Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Alport__Syndrome" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17403.s18">
        <title>References</title>
        <ref id="article-17403.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Renal, auricular, and ocular outcomes of Alport syndrome and their current management.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1309</fpage>
            <page-range>1309-1316</page-range>
            <pub-id pub-id-type="pmid">28864840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Watson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <chapter-title>Alport Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">29262041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashtan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome: facts and opinions.</article-title>
            <source>F1000Res</source>
            <year>2017</year>
            <volume>6</volume>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">28163907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome: deducing the mode of inheritance from the presence of haematuria in family members.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-66</page-range>
            <pub-id pub-id-type="pmid">30506145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation.</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>267</fpage>
            <page-range>267-270</page-range>
            <pub-id pub-id-type="pmid">30410383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zietse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Geel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cransberg</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing Alport Syndrome: Lessons from the Pediatric Ward.</article-title>
            <source>Nephron</source>
            <year>2018</year>
            <volume>140</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-210</page-range>
            <pub-id pub-id-type="pmid">30212818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furusawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unagami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katsumata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yokoo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>K</given-names>
              </name>
              <collab>Japan Academic Consortium of Kidney Transplantation (JACK)</collab>
            </person-group>
            <article-title>Long-term survival in Japanese renal transplant recipients with Alport syndrome: a retrospective study.</article-title>
            <source>BMC Nephrol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>03</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>249</fpage>
            <pub-id pub-id-type="pmid">30285655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crockett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Pont-Kingdon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gedge</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sumner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seamons</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lyon</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Alport syndrome COL4A5 variant database.</article-title>
            <source>Hum Mutat</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>E1652</fpage>
            <page-range>E1652-7</page-range>
            <pub-id pub-id-type="pmid">20574986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nozu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Ohtsubo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ninchoji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishimori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morisada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matsunoshita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kamiyoshi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iijima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV &#x003b1;5 chain.</article-title>
            <source>Kidney Int</source>
            <year>2014</year>
            <month>May</month>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>1208</fpage>
            <page-range>1208-13</page-range>
            <pub-id pub-id-type="pmid">24304881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nozu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minamikawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yanagita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morisada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujinaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gotoh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morishita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ninchoji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morioka</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vorechovsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iijima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis.</article-title>
            <source>J Hum Genet</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>62</volume>
            <issue>7</issue>
            <fpage>733</fpage>
            <page-range>733-735</page-range>
            <pub-id pub-id-type="pmid">28275241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hicks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mierau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wartchow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eldin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Renal diseases associated with hematuria in children and adolescents: a brief tutorial.</article-title>
            <source>Ultrastruct Pathol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">22292732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warady</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stenvinkel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Alport Syndrome Classification and Management.</article-title>
            <source>Kidney Med</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>639</fpage>
            <page-range>639-649</page-range>
            <pub-id pub-id-type="pmid">33094278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Colville</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rheault</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gear</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lagas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flinter</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Alport Syndrome in Women and Girls.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2016</year>
            <month>Sep</month>
            <day>07</day>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>1713</fpage>
            <page-range>1713-1720</page-range>
            <pub-id pub-id-type="pmid">27287265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deltas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pierides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Voskarides</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics of familial hematuric diseases.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>2946</fpage>
            <page-range>2946-60</page-range>
            <pub-id pub-id-type="pmid">24046192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallerini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dosa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Del Prete</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feriozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Clementi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>La Manna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miglietti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mandrile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ghiggeri</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Piaggio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brancati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Frate</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pinciaroli</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Giani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castorina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bresin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giachino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Marchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bruttini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Renieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ariani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.</article-title>
            <source>Clin Genet</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>252</fpage>
            <page-range>252-7</page-range>
            <pub-id pub-id-type="pmid">24033287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morini&#x000e8;re</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hilbert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebbah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Topa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bole-Feysot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pruvost</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nitschke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Plaisier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Knebelmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Macher</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Gubler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heidet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Improving mutation screening in familial hematuric nephropathies through next generation sequencing.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>2740</fpage>
            <page-range>2740-51</page-range>
            <pub-id pub-id-type="pmid">24854265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delimont</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dufek</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Zallocchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gratton</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Laminin &#x003b1;2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>e99083</fpage>
            <pub-id pub-id-type="pmid">24915008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dufek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Delimont</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gratton</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Endothelin A receptor activation on mesangial cells&#x000a0;initiates Alport glomerular disease.</article-title>
            <source>Kidney Int</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>300</fpage>
            <page-range>300-310</page-range>
            <pub-id pub-id-type="pmid">27165837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunwar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ballester</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Noelken</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sado</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ninomiya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome.</article-title>
            <source>J Biol Chem</source>
            <year>1998</year>
            <month>Apr</month>
            <day>10</day>
            <volume>273</volume>
            <issue>15</issue>
            <fpage>8767</fpage>
            <page-range>8767-75</page-range>
            <pub-id pub-id-type="pmid">9535854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosgrove</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bovard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gilroy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kotelianski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gotwals</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amatucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalluri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.</article-title>
            <source>Am J Pathol</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>157</volume>
            <issue>5</issue>
            <fpage>1649</fpage>
            <page-range>1649-59</page-range>
            <pub-id pub-id-type="pmid">11073824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosgrove</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Glomerular pathology in Alport syndrome: a molecular perspective.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>885</fpage>
            <page-range>885-90</page-range>
            <pub-id pub-id-type="pmid">21455721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olaru</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Sado</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Borza</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Quaternary epitopes of &#x003b1;345(IV) collagen initiate Alport post-transplant anti-GBM nephritis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2013</year>
            <month>May</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>889</fpage>
            <page-range>889-95</page-range>
            <pub-id pub-id-type="pmid">23620401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Colon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giannico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abul-Ezz</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Borza</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>3563</fpage>
            <page-range>3563-71</page-range>
            <pub-id pub-id-type="pmid">16236801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borza</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Autoepitopes and alloepitopes of type IV collagen: role in the molecular pathogenesis of anti-GBM antibody glomerulonephritis.</article-title>
            <source>Nephron Exp Nephrol</source>
            <year>2007</year>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>e37</fpage>
            <page-range>e37-43</page-range>
            <pub-id pub-id-type="pmid">17570938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome and thin glomerular basement membrane disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>1736</fpage>
            <page-range>1736-50</page-range>
            <pub-id pub-id-type="pmid">9727383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorner</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome and thin basement membrane nephropathy.</article-title>
            <source>Nephron Clin Pract</source>
            <year>2007</year>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>c82</fpage>
            <page-range>c82-8</page-range>
            <pub-id pub-id-type="pmid">17570934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patey-Mariaud de Serre</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garfa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bessi&#x000e9;res</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Knebelmann</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients.</article-title>
            <source>Kidney Int</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>512</fpage>
            <page-range>512-6</page-range>
            <pub-id pub-id-type="pmid">17554254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gubler</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Alport syndrome without biopsy?</article-title>
            <source>Pediatr Nephrol</source>
            <year>2007</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>621</fpage>
            <page-range>621-5</page-range>
            <pub-id pub-id-type="pmid">17143627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gubler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Broyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naizot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gonzales</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Alport's syndrome. A report of 58 cases and a review of the literature.</article-title>
            <source>Am J Med</source>
            <year>1981</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>493</fpage>
            <page-range>493-505</page-range>
            <pub-id pub-id-type="pmid">7211891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Izzedine</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tankere</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Launay-Vacher</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ear and kidney syndromes: molecular versus clinical approach.</article-title>
            <source>Kidney Int</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>369</fpage>
            <page-range>369-85</page-range>
            <pub-id pub-id-type="pmid">14717907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Colville</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Dagher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fassett</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guymer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the peripheral retinopathy in X-linked and autosomal recessive Alport syndrome.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <page-range>104-8</page-range>
            <pub-id pub-id-type="pmid">17071739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrne</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Budisavljevic</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Ploth</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Renal transplant in patients with Alport's syndrome.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>769</fpage>
            <page-range>769-75</page-range>
            <pub-id pub-id-type="pmid">11920343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jungers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nfeld</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Delons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zenatti</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Perimacular changes in Alport's syndrome.</article-title>
            <source>Clin Nephrol</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>163</fpage>
            <page-range>163-7</page-range>
            <pub-id pub-id-type="pmid">7379367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Giant macular hole in Alport syndrome.</article-title>
            <source>Ophthalmic Genet</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-7</page-range>
            <pub-id pub-id-type="pmid">20450313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plevov&#x000e1;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gut</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janda</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Familial hematuria: A review.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2017</year>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">28236514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosgrove</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.</article-title>
            <source>Matrix Biol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>57-58</volume>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">27576055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Citirik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Batman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Men</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tuncel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zilelioglu</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Electron microscopic examination of the anterior lens capsule in a case of Alport's syndrome.</article-title>
            <source>Clin Exp Optom</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>367</fpage>
            <page-range>367-70</page-range>
            <pub-id pub-id-type="pmid">17697183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kamae</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Deangelis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hageman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Temporal macular thinning associated with X-linked Alport syndrome.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>777</fpage>
            <page-range>777-82</page-range>
            <pub-id pub-id-type="pmid">23572034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raimundo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Figueira</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bilateral giant macular holes: A rare manifestation of Alport syndrome.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>NP13</fpage>
            <page-range>NP13-NP16</page-range>
            <pub-id pub-id-type="pmid">29873249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uliana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mucciolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meloni</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Izzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruttini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Renieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salviati</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2011</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>717</fpage>
            <page-range>717-24</page-range>
            <pub-id pub-id-type="pmid">21380622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liapis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Red cell traverse through thin glomerular basement membrane.</article-title>
            <source>Kidney Int</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>762</fpage>
            <page-range>762-3</page-range>
            <pub-id pub-id-type="pmid">11849422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheong</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kleppel</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome.</article-title>
            <source>Lab Invest</source>
            <year>1994</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-7</page-range>
            <pub-id pub-id-type="pmid">8176894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gyoneva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dorfman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>VH</given-names>
              </name>
            </person-group>
            <article-title>Mechanical response of wild-type and Alport murine lens capsules during osmotic swelling.</article-title>
            <source>Exp Eye Res</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>113</volume>
            <fpage>87</fpage>
            <page-range>87-91</page-range>
            <pub-id pub-id-type="pmid">23707242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ariani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bruttini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Renieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Deltas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Flinter</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Nagel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shagam</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ars</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoefele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garosi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Expert consensus guidelines for the genetic diagnosis of Alport syndrome.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>1175</fpage>
            <page-range>1175-1189</page-range>
            <pub-id pub-id-type="pmid">29987460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rumpelt</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations.</article-title>
            <source>Clin Nephrol</source>
            <year>1980</year>
            <month>May</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>203</fpage>
            <page-range>203-7</page-range>
            <pub-id pub-id-type="pmid">7398144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gettelfinger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Syndromic Hearing Loss: A Brief Review of Common Presentations and Genetics.</article-title>
            <source>J Pediatr Genet</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">29441214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Easson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hearing-impaired young people - a physician's guide&#x02002;.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>521</fpage>
            <page-range>521-524</page-range>
            <pub-id pub-id-type="pmid">29196352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Licht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>T&#x000f6;nshoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>H&#x000f6;cker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wygoda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ehrich</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rascher</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>D&#x000f6;tsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Wiefel</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hoyer</surname>
                <given-names>P</given-names>
              </name>
              <collab>Study Group Members of the Gesellschaft f&#x000fc;r P&#x000e4;diatrische Nephrologie</collab>
              <name>
                <surname>Knebelmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pirson</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Grunfeld</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Niaudet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cochat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heidet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lebbah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Friede</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.</article-title>
            <source>Kidney Int</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>494</fpage>
            <page-range>494-501</page-range>
            <pub-id pub-id-type="pmid">22166847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cravedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alpa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roccatello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gamba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaspari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruggenenti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.</article-title>
            <source>Nephron</source>
            <year>2015</year>
            <volume>130</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-20</page-range>
            <pub-id pub-id-type="pmid">25895746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>T&#x000f6;nshoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Latta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fehrenbach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lange-Sperandio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zappel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Staude</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gellermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Galiano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoecker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ehren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lerch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boeckhaus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friede</surname>
                <given-names>T</given-names>
              </name>
              <collab>German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators</collab>
            </person-group>
            <article-title>A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.</article-title>
            <source>Kidney Int</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>1275</fpage>
            <page-range>1275-1286</page-range>
            <pub-id pub-id-type="pmid">32299679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicklason</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beltz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farahani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colville</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Corneal endothelial cell abnormalities in X-linked Alport syndrome.</article-title>
            <source>Ophthalmic Genet</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-19</page-range>
            <pub-id pub-id-type="pmid">32159412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Knebelmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Drouot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Desch&#x000ea;nes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hors-Cayla</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tryggvason</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nfeld</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Broyer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression.</article-title>
            <source>J Clin Invest</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>1195</fpage>
            <page-range>1195-207</page-range>
            <pub-id pub-id-type="pmid">8132760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hudson</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Kalluri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gunwar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ballester</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Noelken</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Sarras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Saus</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation.</article-title>
            <source>Kidney Int</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>179</fpage>
            <page-range>179-87</page-range>
            <pub-id pub-id-type="pmid">1635348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brainwood</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kashtan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gubler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation.</article-title>
            <source>Kidney Int</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>762</fpage>
            <page-range>762-6</page-range>
            <pub-id pub-id-type="pmid">9507224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalluri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Smeets</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Schroder</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lemmink</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Boutaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neilson</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome.</article-title>
            <source>Kidney Int</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>1199</fpage>
            <page-range>1199-204</page-range>
            <pub-id pub-id-type="pmid">7783419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tryggvason</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hostikka</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shows</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics of Alport syndrome.</article-title>
            <source>Kidney Int</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">8433568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome.</article-title>
            <source>Kidney Int</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>1445</fpage>
            <page-range>1445-63</page-range>
            <pub-id pub-id-type="pmid">8914010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qu&#x000e9;rin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nfeld</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Droz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahieu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kreis</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Linear glomerular IgG fixation in renal allografts: incidence and significance in Alport's syndrome.</article-title>
            <source>Clin Nephrol</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>134</fpage>
            <page-range>134-40</page-range>
            <pub-id pub-id-type="pmid">3514017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashtan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Butkowski</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kleppel</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>First</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome.</article-title>
            <source>J Lab Clin Med</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>116</volume>
            <issue>4</issue>
            <fpage>508</fpage>
            <page-range>508-15</page-range>
            <pub-id pub-id-type="pmid">2212860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kajimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Terasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunugi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pathologic glomerular characteristics and glomerular basement membrane alterations in biopsy-proven thin basement membrane nephropathy.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2019</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>638</fpage>
            <page-range>638-649</page-range>
            <pub-id pub-id-type="pmid">30687875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gangemi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giannakakis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Crisafi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faraggiana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fallerini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Renieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muda</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport syndrome.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2013</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>749</fpage>
            <page-range>749-55</page-range>
            <pub-id pub-id-type="pmid">23371956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jais</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Knebelmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giatras</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>De Marchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rizzoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Renieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Netzer</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Flinter</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pirson</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wieslander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Persson</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Tryggvason</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Saus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Antignac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smeets</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gubler</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>2603</fpage>
            <page-range>2603-10</page-range>
            <pub-id pub-id-type="pmid">14514738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rheault</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Women and Alport syndrome.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-6</page-range>
            <pub-id pub-id-type="pmid">21380623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17403.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallerini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baldassarri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trevisson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morbidoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>La Manna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lazzarin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barbano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pinciaroli</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Garosi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frullanti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mencarelli</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Renieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ariani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Alport syndrome: impact of digenic inheritance in patients management.</article-title>
            <source>Clin Genet</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-44</page-range>
            <pub-id pub-id-type="pmid">27859054</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
